William Blair Reiterates Outperform Rating on Eagle Pharmaceuticals (EGRX), Sees Multiple Possibilities for Further Upside

March 28, 2022 11:56 AM EDT Send to a Friend
William Blair analyst Tim Lugo reiterated an Outperform rating on Eagle Pharmaceuticals (NASDAQ: EGRX), following the company's announcement of acquisition ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login